

**Amendments to the Specification:**

Please amend the specification as follows:

Please replace paragraph immediately following the Title, with the following rewritten paragraph:

This application is a continuation-in-part of United States Serial No. 09/337,756, filed June 22, 1999, which, in turn, claims priority to Provisional Appl. Ser. Nos. 60/090,142; and 60/104,156, filed June 22, 1998 and October 14, 1998, respectively, the contents of which are incorporated herein by reference in their entirety.

Please delete the paragraph on page 24, lines 11 – 23 and replace it with the following paragraph:

The invention further contemplates the use of the inventive bsAb and the diagnostic agent(s) in the context of Boron Neutron Capture Therapy (BNCT) protocols. BNCT is a binary system designed to deliver ionizing radiation to tumor cells by neutron irradiation of tumor-localized  $^{10}\text{B}$  atoms. BNCT is based on the nuclear reaction which occurs when a stable isotope, isotopically enriched  $^{10}\text{B}$  (present in 19.8% natural abundance), is irradiated with thermal neutrons to produce an alpha particle and a  $^7\text{Li}$  nucleus. These particles have a path length of about one cell diameter, resulting in high linear energy transfer. Just a few of the short-range 1.7 MeV alpha particles produced in this nuclear reaction are sufficient to target the cell nucleus and destroy it. Success with BNCT of cancer requires methods for localizing a high concentration of  $^{10}\text{B}$  at tumor sites, while leaving non-target organs essentially boron-free. Compositions and methods for treating tumors in subjects using pre-targeting bsAb for BNCT are described in co-pending Patent Appl. Serial No. 09/205,243, now U.S. Patent No. 6,228,362, and can easily be modified for the purposes of the present invention.